Old Web
English
Sign In
Acemap
>
authorDetail
>
Grace Hirakata
Grace Hirakata
Minimal residual disease
Medicine
Internal medicine
Cyclophosphamide
Immunology
3
Papers
15
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study
2019
Blood Advances
Michael O’Dwyer
Robert Henderson
Serika D. Naicker
Mary R. Cahill
Philip Murphy
Vitaliy Mykytiv
John Quinn
Cian McEllistrim
Janusz Krawczyk
Jessica Walsh
Elizabeth Lenihan
Tara Kenny
A. Hernando
Grace Hirakata
Imelda Parker
E Kinsella
G. Gannon
Alessandro Natoni
Kevin Lynch
Aideen E. Ryan
Show All
Source
Cite
Save
Citations (15)
Cybord-Dara Is a Highly Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Initial Efficacy Results of the 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study
2018
Blood
Robert Henderson
Mary R. Cahill
Philip Murphy
Vitaliy Mykytiv
John Quinn
Jessica Walsh
Elizabeth Lenihan
Tara Kenny
A. Hernándo
Grace Hirakata
Imelda Parker
Emma Kinsella
Grainne Gannon
Alessandro Natoni
Michael O’Dwyer
Show All
Source
Cite
Save
Citations (0)
Weekly CyborD-DARA Is a Safe and Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Preliminary Results of the Early Phase 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study
2017
Blood
Cian McEllistrim
Mary R. Cahill
Philip Murphy
Vitaliy Mykytiv
John Quinn
Amanda Bray
Jessica Walsh
Elizabeth Lenihan
Tara Kenny
Grace Hirakata
Imelda Parker
A. Hernando
Michael O’Dwyer
Show All
Source
Cite
Save
Citations (0)
1